Clinical trials: Solid Tumors, Adult, open to volunteers
PET / CT, Solid Tumors
Evaluation of the Diagnostic Efficacy of a αvβ6/FAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors
Malignant tumors pose a grave threat to human health and impose a substantial burden on society. Molecular imaging, which enables non-invasive, in vivo visualization of biological processes at the molecular level, is crucial for…
- Conditions
- PET / CT, Solid Tumors, Adult
- Trial name
- NCT07385950
- Testing
- PET/CT Imaging with αvβ6/FAP-targeted tracer
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhongnan Hospital
Non-Small Cell Lung Cancer, Sarcoma
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
Alterations in the HER2 gene are involved in the development of cancer. These abnormalities are found at highly variable rates (from approximately 2% to 60%) in cancers of the lung, breast, stomach, bile ducts, salivary glands…
- Conditions
- Non-Small Cell Lung Cancer, Sarcoma, Head &Amp; Neck Cancer, Colorectal Carcinoma
- Trial name
- AcSé HER2 (NCT07192068)
- Testing
- Zanidatamab
- Where
- 4 sites in France
- Volunteers
- 105 people
- Sponsor
- UNICANCER
Locally Advanced Solid Tumor, Metastatic Solid Tumor
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor…
- Trial name
- NCT06415487
- Testing
- Cyclophosphamide, Fludarabine, ACE2016
- Where
- 9 sites in United States, Taiwan
- Volunteers
- 30 people
- Sponsor
- Acepodia Biotech, Inc.
Hepatocellular Carcinoma
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours…
- Trial name
- RHEA-1 (NCT06795022)
- Testing
- AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy
- Where
- 21 sites in United States, China and 5 more
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors…
- Conditions
- Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
- Trial name
- Luca-1 (NCT07705334)
- Testing
- SHY-ONC6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- SHY Therapeutics
Solid Tumor, Adult
First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
This multicenter, open-label, first-in-human, Phase 1/2 study consists of a Part 1 (Phase 1) open-label dose escalation of EGL-001 administered as a single agent and in combination with an anti-PD(L)-1 treatment, followed by a…
- Trial name
- NCT06622486
- Testing
- EGL-001
- Where
- 8 sites in France, Spain
- Volunteers
- 50 people
- Sponsor
- Egle Therapeutics
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
Advanced Solid Cancer
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
This is an open-label,multicenter phase I study to evaluate the safety,Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0609 in Adult Participants with Locally Advanced/Metastatic Solid Tumors
- Trial name
- Solid Tumors (NCT07265921)
- Testing
- SIM0609 for injection, dose expansion of SIM0609 in CRC, dose expansion of SIM0609 in GC/GEJC cohort
- Where
- 6 sites in China
- Volunteers
- 232 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Solid Tumor, Adult
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion
The NRG1 gene is located on chromosome 8 (8p12 region) and encode NRG1. NRG1 gene is translated to generate six different proteins (I-VI) and at least 31 isoforms.
- Trial name
- NCT06383884
- Testing
- Patritumab Deruxtecan
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Solid Tumor, Adult, DC
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
Placental or tumor-derived heat shock protein gp96 is collected, purified, and stored. The DC cells are isolated from the patient's blood and then cocultured with the gp96 to obtain the activated DC cell product.
- Trial name
- NCT06477614
- Testing
- DC cell Vaccine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original…
- Trial name
- NCT07213817
- Testing
- IPN60300
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 114 people
- Sponsor
- Ipsen
Advanced or Metastatic Solid Tumors
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer.
- Trial name
- NCT07205718
- Testing
- TAK-188
- Where
- 15 sites in United States
- Volunteers
- 273 people
- Sponsor
- Takeda
Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult…
- Conditions
- Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT07169734
- Testing
- ALE.P03
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 180 people
- Sponsor
- Alentis Therapeutics AG
Adult With Solid Cancer
CIRculating CANcer MAster-Protocol
This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease
- Trial name
- CIRCAN MAP (NCT05089747)
- Testing
- Blood sampling for biomarker analysis (microRNA, circulating DNA…)
- Where
- 7 sites in France
- Volunteers
- 6,000 people
- Sponsor
- Hospices Civils de Lyon
Lung Cancer, Non-small Cell, Lung Cancer Metastatic
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local…
- Conditions
- Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer
- Trial name
- KYANITE-1 (NCT06228326)
- Testing
- KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy
- Where
- 14 sites in United States
- Volunteers
- 250 people
- Sponsor
- Krystal Biotech, Inc.
Advanced Solid Tumor
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Phase 1/2 Study for IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
- Trial name
- NCT07508761
- Testing
- IPG7236, Toripalimab Injection
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Solid Tumor Malignancies
Clinical Evaluation of [68Ga]Ga-FFD PET Imaging in Healthy Volunteers and Patients With Solid Tumors
This is a prospective, single-center, open-label clinical study designed to evaluate the safety, biodistribution, radiation dosimetry, and diagnostic performance of [68Ga]Ga-FFD PET imaging.
- Trial name
- NCT07708103
- Testing
- [68Ga]Ga-FFD
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Solid and Hematologic Cancer
Feasibility Study of a Sports-Inspired Onco-Coaching Progranm for Young Adults i Cancer Remission
This is a single-center, non-randomized feasibility study. For this study, 19 young adults treated for cancer at the Paoli-Calmettes Institute will be included.This study includes interviews and questionnaires to assess the…
- Trial name
- rebond-jas (NCT07861971)
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Institut Paoli-Calmettes
Refractory Cancer, Recurrent Cancer
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors.
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
- Trial name
- NCT05958121
- Testing
- IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy
- Where
- 29 sites in Germany, Netherlands
- Volunteers
- 400 people
- Sponsor
- Immatics Biotechnologies GmbH